Anika Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M | $119.9M | $120.8M | $113.8M | $147.8M | $130.5M | $114.6M | $105.6M |
| Cost of Revenue | $49.0M | $43.9M | $38.3M | $40.6M | $64.9M | $61.4M | $28.7M | $31.3M |
| Gross Profit | $63.8M | $76.0M | $82.5M | $73.2M | $82.9M | $69.0M | $85.9M | $74.3M |
| Gross Margin | 56.6% | 63.4% | 68.3% | 64.3% | 56.1% | 52.9% | 74.9% | 70.4% |
| Operating Expenses | ||||||||
| Research & Development | $25.8M | $25.5M | $21.8M | $18.3M | $27.3M | $23.4M | $16.7M | $18.2M |
| SG&A Expense | $49.1M | $55.6M | $59.9M | $51.2M | $74.1M | $60.1M | $35.0M | $34.3M |
| Operating Income | $-11.1M | $-5.1M | $844.0K | $3.7M | $2.6M | $-28.3M | $34.2M | $21.7M |
| Operating Margin | -9.8% | -4.3% | 0.7% | 3.2% | 1.8% | -21.7% | 29.9% | 20.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-9.3M | $-2.8M | $3.2M | $4.3M | $2.4M | $-28.6M | $36.1M | $23.2M |
| Income Tax Expense | $672.0K | $6.1M | $6.6M | $2.1M | $-1.7M | $-4.6M | $8.9M | $4.5M |
| Net Income | $-10.9M | $-56.4M | $-82.7M | $-14.9M | $4.1M | $-24.0M | $27.2M | $18.7M |
| Net Margin | -9.6% | -47.0% | -68.4% | -13.1% | 2.8% | -18.4% | 23.7% | 17.7% |
| EPS (Basic) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.29 | $-1.69 | $1.93 | $1.30 |
| EPS (Diluted) | $-0.76 | $-3.83 | $-5.64 | $-1.02 | $0.28 | $-1.69 | $1.89 | $1.27 |
| Shares Outstanding (Basic) | 14.3M | 14.7M | 14.7M | 14.6M | 14.4M | 14.2M | 14.1M | 14.4M |
| Shares Outstanding (Diluted) | 14.3M | 14.7M | 14.7M | 14.8M | 14.6M | 14.2M | 14.4M | 14.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |